BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12054736)

  • 1. Dimerization of v-erbA on inverted repeats.
    Zubkova I; Subauste JS
    Biochem Biophys Res Commun; 2002 May; 294(1):35-41. PubMed ID: 12054736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequences required for the transition from monomeric to homodimeric forms of thyroid hormone receptor alpha and v-erbA.
    Zubkova I; Subauste JS
    Mol Cell Endocrinol; 2003 Jan; 199(1-2):61-72. PubMed ID: 12581880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirements for repression of retinoid X receptor by the oncoprotein P75gag-v-erbA and the thyroid hormone receptors.
    Wahlström GM; Vennström B
    Mol Endocrinol; 1998 May; 12(5):645-53. PubMed ID: 9605927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncoprotein P75gag-v-erbA represses thyroid hormone induced transcription only via response elements containing palindromic half-sites.
    Wahlström GM; Harbers M; Vennström B
    Oncogene; 1996 Aug; 13(4):843-52. PubMed ID: 8761306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of DNA binding sites for the V-erbA oncoprotein, the viral homolog to thyroid hormone receptor alpha.
    Harbers M; Wahlström GM; Vennström B
    J Steroid Biochem Mol Biol; 1998 Nov; 67(3):181-91. PubMed ID: 9879977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimerization interfaces of v-erbA homodimers and heterodimers with retinoid X receptor alpha.
    Shen Q; Subauste JS
    J Biol Chem; 2000 Dec; 275(52):41018-27. PubMed ID: 11018031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V-erba homodimers mediate the potent dominant negative activity of v-erba on everted repeats.
    Zubkova I; Subauste JS
    Mol Biol Rep; 2004 Jun; 31(2):131-7. PubMed ID: 15293789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V-erbA requires auxiliary proteins for dominant negative activity.
    Hermann T; Hoffmann B; Piedrafita FJ; Zhang XK; Pfahl M
    Oncogene; 1993 Jan; 8(1):55-65. PubMed ID: 8093812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the DNA-binding and dominant negative activity of v-erbA homodimers.
    Subauste JS; Koenig RJ
    Mol Endocrinol; 1998 Sep; 12(9):1380-92. PubMed ID: 9731706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A choice between transcriptional enhancement and repression by the v-erbA oncoprotein governed by one nucleotide in a thyroid hormone responsive half site.
    Andersson ML; Vennström B
    Oncogene; 2000 Jul; 19(32):3563-9. PubMed ID: 10951561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of transformation by v-ErbA: substitution for steroid hormone receptor function in self renewal induction.
    Bauer A; Ulrich E; Andersson M; Beug H; von Lindern M
    Oncogene; 1997 Aug; 15(6):701-15. PubMed ID: 9264411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of an inverted repeat with a zero spacer (IR0)-type retinoic acid response element from the mouse nuclear orphan receptor TR2-11 gene.
    Lee CH; Wei LN
    Biochemistry; 1999 Jul; 38(27):8820-5. PubMed ID: 10393558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The v-erbA oncogene requires cooperation with tyrosine kinases to arrest erythroid differentiation induced by ligand-activated endogenous c-erbA and retinoic acid receptor.
    Schroeder C; Gibson L; Beug H
    Oncogene; 1992 Feb; 7(2):203-16. PubMed ID: 1347913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-erbA and v-erbA modulate growth and gene expression of a mouse glial precursor cell line.
    Iglesias T; Llanos S; López-Barahona M; Pérez-Aranda A; Rodríguez-Peña A; Bernal J; Höhne A; Seliger B; Muñoz A
    Cell Growth Differ; 1994 Jul; 5(7):697-704. PubMed ID: 7947384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The v-ErbA oncoprotein quenches the activity of an erythroid-specific enhancer.
    Braliou GG; Ciana P; Klaassen W; Gandrillon O; Stunnenberg HG
    Oncogene; 2001 Feb; 20(7):775-87. PubMed ID: 11314012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein-protein interaction domains and the heterodimerization of thyroid hormone receptor variant alpha2 with retinoid X receptors.
    Wu Y; Yang YZ; Koenig RJ
    Mol Endocrinol; 1998 Oct; 12(10):1542-50. PubMed ID: 9773977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities.
    Hao E; Menke JB; Smith AM; Jones C; Geffner ME; Hershman JM; Wuerth JP; Samuels HH; Ways DK; Usala SJ
    Mol Endocrinol; 1994 Jul; 8(7):841-51. PubMed ID: 7984146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sick euthyroid syndrome is associated with decreased TR expression and DNA binding in mouse liver.
    Beigneux AP; Moser AH; Shigenaga JK; Grunfeld C; Feingold KR
    Am J Physiol Endocrinol Metab; 2003 Jan; 284(1):E228-36. PubMed ID: 12388159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional repression by thyroid hormone receptors. A role for receptor homodimers in the recruitment of SMRT corepressor.
    Yoh SM; Privalsky ML
    J Biol Chem; 2001 May; 276(20):16857-67. PubMed ID: 11278601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor.
    De Luca A; Severino A; De Paolis P; Cottone G; De Luca L; De Falco M; Porcellini A; Volpe M; Condorelli G
    Biochem J; 2003 Feb; 369(Pt 3):477-84. PubMed ID: 12371907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.